Instillido

Lidocaine Hydrochloride, the active ingredient in Instillido, is a local anesthetic presented as a sterile solution for urethral use. It provides temporary loss of sensation to facilitate urethral procedures in adult patients. GNH USA supplies Instillido as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Lidocaine Hydrochloride is used to achieve local anesthesia of the urethral mucosa during procedures.

Urethral procedures: provides temporary loss of sensation to facilitate catheterization, cystoscopy, or endoscopic surgery. Urethral dilatation: eases discomfort during therapeutic dilation of the urethra. Diagnostic urethroscopy: reduces pain and discomfort during visual examination of the urethra.

Lidocaine Hydrochloride may cause a range of adverse reactions at the site of administration or systemically.

Common Side Effects: - Burning or stinging sensation at the application site. - Mild local irritation or erythema. - Transient urinary urgency or frequency. - Slight taste alteration if solution contacts oral mucosa. - Temporary mild headache.

Serious or Rare Side Effects: - Allergic reaction such as rash, angioedema, or anaphylaxis. - Systemic toxicity presenting as central nervous system symptoms (dizziness, seizures, confusion). - Cardiac arrhythmias or conduction disturbances. - Severe hypotension. - Respiratory depression in extreme overdose.

When using Instillido, several precautions should be observed to ensure patient safety.

Assess patient history: verify any known lidocaine or amide‑type anesthetic allergy. Avoid excessive dose: adhere strictly to recommended volume for urethral application. Monitor for systemic signs: watch for CNS or cardiac symptoms indicating possible toxicity. Use with caution in hepatic impairment: reduced metabolism may increase systemic exposure. Avoid concurrent use with other local anesthetics: risk of additive toxicity. Store at room temperature: keep in original container, protect from light and moisture.

Lidocaine Hydrochloride can interact with other medications, affecting its safety profile.

Major Interactions (Avoid): - Class I antiarrhythmic drugs (e.g., quinidine, procainamide): may enhance cardiotoxicity. - Beta‑blockers (e.g., propranolol): increase risk of bradycardia. - General anesthetics (e.g., propofol): additive central nervous system depression. - Monoamine oxidase inhibitors: may potentiate hypotensive effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin): may increase lidocaine plasma levels. - CYP1A2 inducers (e.g., carbamazepine): may reduce lidocaine efficacy. - Non‑steroidal anti‑inflammatory drugs: may increase local irritation. - Diuretics (e.g., furosemide): can alter plasma protein binding of lidocaine.